News & Events

< Back to News Overview

AirXpanders' AeroFormĀ® Tissue Expander System Showcased at Barcelona Breast Meeting

21 / 03 / 2017

PALO ALTO, Calif., March 21, 2017 /PRNewswire/ -- AirXpanders, Inc. (ASX: AXP) (AirXpanders or Company), a medical device company focused on the design,
manufacture, sale and distribution of the AeroForm® Tissue Expander System,
today announced that the AeroForm technology was featured at the prestigious
Barcelona Breast Meeting (BBM), which took place March 16-17, in Barcelona,


The BBM brings together plastic surgeons and microsurgeons from Europe to educate them on the latest products and research developments in breast reconstructive and breast aesthetic surgery. During BBM, Kamakshi Zeidler, M.D., FACS, a board-certified plastic surgeon and Managing Partner at Aesthetx in Campbell, California, reviewed the results from the XPAND randomized clinical trial and shared her personal experience treating patients with the AeroForm System. Dr. Zeidler served as a clinical investigator for AirXpanders' U.S. XPAND and XPAND II clinical trials and recently performed the first commercial AeroForm procedure in the U.S. following FDA's de novo marketing authorization.

Additionally, AeroForm was featured during the Gadget Show, which focuses
specifically on the latest innovations in breast reconstruction. AirXpanders'
President and CEO, Scott Dodson, provided an overview of the breakthrough

"With the commercial launch of AeroForm now underway in the United States, our next goal is to connect with a global network of reconstructive experts," said Dodson. "The interest and excitement in AeroForm during BBM was palpable, and we look forward to working with these experts to identify a path to make our technology available in Europe in the future."

AeroForm offers a needle-free alternative for women who choose reconstructive surgery following a mastectomy. AeroForm is activated by a handheld wireless controller that administers small amounts of carbon dioxide (CO[2]) up to three times a day, to gradually stretch the tissue to prepare for a breast implant. With the push of a button from the wireless controller, a preprogrammed amount of CO[2 ]is delivered in seconds, allowing the patient to continue with her daily activities while preparing for reconstruction.

About AirXpanders:

Founded in 2005, AirXpanders, Inc. ( designs, manufactures and markets innovative medical devices to improve breast reconstruction. The company's AeroForm Tissue Expander System is used in patients undergoing two-stage breast reconstruction following mastectomy. Headquartered in Palo Alto, California, AirXpanders' vision is to be the global leader in reconstructive surgery products and to become the standard of care in wo-stage breast reconstruction. AirXpanders is a publicly-listed company on the Australian Securities Exchange under the symbol "AXP." AeroForm was granted U.S. FDA de novo marketing authorization in 2016, first CE mark in Europe in 2012 and is currently approved for sale in Australia. 

Forward-Looking Statements

This announcement contains or may contain forward-looking statements that are based on management's beliefs, assumptions and expectations and on information currently available to management.

All statements that address operating performance, events or developments that we expect or anticipate will occur in the future are forward-looking statements. These include, without limitation, European market acceptance and U.S. sales of our product.

Management believes that these forward-looking statements are reasonable when made. You should not place undue reliance on forward-looking statements because they speak only as of the date when made. AirXpanders does not assume any obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise. AirXpanders may not actually achieve the plans, projections or expectations disclosed in forward-looking statements. Actual results, developments or events could differ materially from those disclosed in the forward-looking statements.

For more information, refer to the Company's website at